However, it is possible that specific genetic subsets of TP53-mutant AML, such as those with concurrent TET2 mutations, may still derive benefit from CD47-targeted therapies, particularly when combined with other immune-modulating strategies, such as TIGIT blockade. The gene discussed is TP53; the disease is acute myeloid leukemia.